The role of Epstein-Barr virus in epithelial malignancies

Journal of Pathology

Volumn 235, Issue 2, 2015, Pages 323-333

  Tsao, Sai Wah ^a   Tsang, Chi Man ^a   To, Ka Fai ^b,c   Lo, Kwok Wai ^b,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BART s; Epstein Barr virus; Gastric carcinoma; LMP1; Lymphoeptithelioma like carcinomas; Nasopharyngeal carcinoma

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MICRORNA;

APOPTOSIS; ARTICLE; BAMH1 GENE; BART GENE; EPITHELIUM CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GENE PRODUCT; HOST CELL; IMMUNE EVASION; INFLAMMATION; LATENT VIRUS INFECTION; MALIGNANT TRANSFORMATION; NASOPHARYNX CARCINOMA; PRECANCER; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS GENE; ANIMAL; BIOPSY; COMPLICATION; GENETICS; GENOTYPE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; MOLECULAR PATHOLOGY; NEOPLASM; PATHOGENICITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK FACTOR; VIROLOGY; VIRULENCE; VIRUS ACTIVATION; VIRUS LATENCY;

ANIMALS; BIOPSY; EPSTEIN-BARR VIRUS INFECTIONS; GENOTYPE; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; PATHOLOGY, MOLECULAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; VIROLOGY; VIRULENCE; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84917705494     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4448     Document Type: Article

References (106)

1. Cohen JI, Fauci AS, Varmus H, et al. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 2011; 3: 107fs7.
2. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768.
3. Vockerodt M, Yap L-F, Shannon-Lowe C, et al. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol 2015; 235: 312-322.
4. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47: 883-889.
5. Pittaluga S, Loke SL, So KC, et al. Clonal Epstein-Barr virus in lymphoepithelioma-like carcinoma of the stomach: demonstration of viral genome by in situ hybridization and Southern blot analysis. Mod Pathol 1992; 5: 661-664.
6. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004; 5: 423-428.
7. Chan JK, Bray F, McCarron, et al. Nasopharyngeal carcinoma. In Pathology and Genetics. Head and Neck Tumors, Barnes L, Eveson JW, Reichart P, et al. (eds). : IARC Press: Lyon, 2005; 85-97.
8. Shibata D, Tokunaga M, Uemura Y, et al. Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infltration. Lymphoepithelioma-like carcinoma. Am J Pathol 1991; 139: 469-474.
9. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adeno-carcinoma. Am J Pathol 1992; 140: 769-774.
10. Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol 1995; 103: 308-315.
11. Chan AW, Tong JH, Sung MY, et al. Epstein-Barr virus associated lymphoepithelioma-like cholangiocarcinoma: arare variant ofintra-hepatic cholangiocarcinoma with favorable outcome. Histopathol-ogy 2014; 65: 674-683.
12. Rickinson AB. Co-infections, infammation and oncogenesis: future directions for EBV research. Semin Cancer Biol 2014; 26: 99-115.
13. Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profling identify new driver mutations in gastric cancer. Nat Genet 2014; 46: 573-582.
14. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209.
15. Thorley-Lawson DA, Hawkins JB, Tracy SI, et al. The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol 2013; 3: 227-232.
16. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 2002; 8: 594-599.
17. Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol 2007; 81: 7825-7832.
18. Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 2003; 9: 307-314.
19. Tsang CM, Zhang G, Seto E, et al. Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization. Int J Cancer 2010; 127: 1570-1583.
20. Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333: 693-698.
21. Chan AS, To KF, Lo KW, et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 2000; 60: 5365-5370.
22. Longnecker RM, Kieff E, Cohen JI. Epstein-Barr virus. In Fields Vi ro logy, Knipe DM, Howley PM (eds). Lippincott Williams & Wilkins: Philadelphia, PA, 2013; 1898-1959.
23. Tsao SW, Tsang CM, Pang PS, et al. The biology of EBV infection in human epithelial cells. Semin Cancer Biol 2012; 22: 137-143.
24. Marquitz AR, Mathur A, Chugh PE, et al. Expression profle of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J Virol 2014; 88: 1389-1393.
25. Strong MJ, Xu G, Coco J, et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog 2013; 9: e1003341.
26. Lung RW, Tong JH, To KF. Emerging roles of small Epstein-Barr virus-derived non-coding RNAs in epithelial malignancy. Int J Mol Sci 2013; 14: 17378-17409.
27. Tsang CM, Yip YL, Lo KW, et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc Natl Acad Sci USA 2012; 109: E3473-3482.
28. Hui AB, Or YY, Takano H, et al. Array-based comparative genomic hybridization analysis identifed cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 2005; 65: 8125-8133.
29. Yip YL, Pang PS, Deng W, et al. Effcient immortalization of primary nasopharyngeal epithelial cells for EBV infection study. PLoS One 2013; 8: e78395.
30. Song LB, Zeng MS, Liao WT, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66: 6225-6232.
31. Young LS, Lau R, Rowe M, et al. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol 1991; 65: 2868-2874.
32. Karimi L, Crawford DH, Speck S, et al. Identifcation of an epithelial cell differentiation responsive region within the BZLF1 promoter of the Epstein-Barr virus. J Gen Virol 1995; 76: 759-765.
33. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 2014; 26: 60-68.
34. Crook T, Nicholls JM, Brooks L, et al. High level expression of 5N-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000; 19: 3439-3444.
35. Wille CK, Nawandar DM, Panfl AR, et al. Viral genome methy-lation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol 2013; 87: 935-950.
36. Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol 2012; 22: 79-86.
37. Daskalogianni C, Pyndiah S, Apcher S, et al. Epstein-Barr virus-encoded EBNA1 and ZEBRA; targets for therapeutic strategies against EBV-carrying cancers. J Pathol 2015; 235: 334-341.
38. Ma SD, Yu X, Mertz JE, et al. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol 2012; 86: 7976-7987.
39. Lee CP, Chen JY, Wang JT, et al. Epstein-Barr virus BGLF4 kinase induces premature chromosome condensation through activation of condensin and topoisomerase II. J Virol 2007; 81: 5166-5180.
40. Fang CY, Lee CH, Wu CC, et al. Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Int J Cancer 2009; 124: 2016-2025.
41. Lin DC, Meng X, Hazawa M, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet 2014; 46: 866-871.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
43. Frappier L. Role of EBNA1 in NPC tumourigenesis. Semin Cancer Biol 2012; 22: 154-161.
44. Sivachandran N, Sarkari F, Frappier L. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog 2008; 4: e1000170.
45. Cao JY, Mansouri S, Frappier L. Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses. J Virol 2012; 86: 382-394.
46. Wood VH, O'Neil JD, Wei W, et al. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFß signaling pathways. Oncogene 2007; 26: 4135-4147.
47. Chung GT, Lou WP, Chow C, et al. Constitutive activation of distinct NF-KB signals in EBV-associated nasopharyngeal carcinoma. J Pathol 2013; 231: 311-322.
48. Takada K, Nanbo A. The role of EBERs in oncogenesis. Semin Cancer Biol 2001; 11: 461-467.
49. Samanta M, Iwakiri D, Takada K. Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene 2008; 27: 4150-4160.
50. Yamamoto N, Takizawa T, Iwanaga Y, et al. Malignant transformation of B lymphoma cell line B JAB by Epstein-Barr virus-encoded small RNAs. FEBS Lett 2000; 484: 153-158.
51. Nanbo A, Inoue K, Adachi-Takasawa K, et al. Epstein-Barr virus RNA confers resistance to interferon-α-induced apoptosis in Burkitt's lymphoma. EMBO J 2002; 21: 954-965.
52. Nanbo A, Yoshiyama H, Takada K. Epstein-Barr virus-encoded poly(A)-RNA confers resistance to apoptosis mediated through Fas by blocking the PKR pathway in human epithelial intestine 407 cells. J Virol 2005; 79: 12280-12285.
53. Marquitz AR, Raab-Traub N. The roleofmiRNAs and EBV BARTs in NPC. Semin Cancer Biol 2012; 22: 166-172.
54. Al-Mozaini M, Bodelon G, Karstegl CE, et al. Epstein-Barr virus BART gene expression. J Gen Virol 2009; 90: 307-316.
55. Smith PR, de Jesus O, Turner D, et al. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol 2000; 74: 3082-3092.
56. Chen H, Huang J, Wu FY, et al. Regulation of expression of the Epstein-Barr virus BamHI-A rightward transcripts. J Virol 2005; 79: 1724-1733.
57. Qiu J, Cosmopoulos K, Pegtel M, et al. A novel persistence associated EBV miRNA expression profle is disrupted in neoplasia. PLoS Pa t h o g 2011; 7: e1002193.
58. Zhu JY, Pfuhl T, Motsch N, et al. Identifcation of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol 2009; 83: 3333-3341.
59. Chen SJ, Chen GH, Chen YH, et al. Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing. PloS One 2010; 5: e12745.
60. Lo AK, To KF, Lo KW, et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA 2007; 104: 16164-16169.
61. Choy EY, Siu KL, Kok KH, et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008; 205: 2551-2560.
62. Marquitz AR, Mathur A, Nam CS, et al. The Epstein-Barr virus BART microRNAs target the pro-apoptotic protein Bim. Virol og y 2011; 412: 392-400.
63. Dölken L, Malterer G, Erhard F, et al. Systematic analysis of viral and cellular microRNA targets in cells latently infected with human γ-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe 2010; 7: 324-334.
64. Nachmani D, Stern-Ginossar N, Sarid R, et al. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009; 5: 376-385.
65. Lung RW, Tong JH, Sung YM, et al. Modulation of LMP2A expression by a newly identifed Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009; 11: 1174-1184.
66. ∗ microRNA in nasopharyngeal carcinoma. Int J Cancer 2013; 133: 79-87.
67. Hsu CY, Yi YH, Chang KP, et al. The Epstein-Barr virus-encoded microRNA MiR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma. PLoS Pathog 2014; 10: e1003974.
68. Jung YJ, Choi H, Kim H, et al. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1. J Virol 2014; 88: 9027-9037.
69. Barth S, Pfuhl T, Mamiani A, et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 2008; 36: 666-675.
70. Hoebe EK, Le Large TY, Greijer AE, et al. BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator. Rev Med Virol 2013; 23: 367-383.
71. Houali K, Wang X, Shimizu Y, et al. A new diagnostic marker for secreted Epstein-Barr virus-encoded LMP1 and BARF1 oncopro-teins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res 2007; 13: 4993-5000.
72. Wei MX, de Turenne-Tessier M, et al. Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus. Oncogene 1997; 14: 3073-3081.
73. Jiang R, Cabras G, Sheng W, et al. Synergism of BARF1 with Ras induces malignant transformation in primary primate epithelial cells and human nasopharyngeal epithelial cells. Neoplasia 2009; 11: 964-973.
74. Tsao SW, Tramoutanis G, Dawson CW, et al. The signifcance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 473-487.
75. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 2012; 22: 144-153.
76. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995; 69: 4390-4398.
77. Horikawa T, Sheen TS, Takeshita H, et al. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopha-ryngeal carcinoma. Am J Pathol 2001; 159: 27-33.
78. Lo AK, Huang DP, Lo KW, et al. Phenotypic alterations induced by the Hong Kong-prevalent Epstein-Barr virus-encoded LMP1 variant (2117-LMP1) in nasopharyngeal epithelial cells. Int J Cancer 2004; 109: 919-925.
79. Lo AK, Dawson CW, Lo KW, et al. Upregulation of Id1 by Epstein-Barr virus-encoded LMP1 confers resistance to TGFβ-mediated growth inhibition. Mol Cancer 2010; 9: 155.
80. Wakisaka N, Kondo S, Yoshizaki T, et al. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1α. Mol Cell Biol 2004; 24: 5223-5234.
81. Lo AK, Lo KW, Ko CW, et al. Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells. J Pathol 2013; 230: 336-346.
82. Horikawa T, Yang J, Kondo S, et al. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res 2007; 67: 1970-1978.
83. Horikawa T, Yoshizaki T, Kondo S, et al. Epstein-Barr virus latent membrane protein 1 induces snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma. Br J Cancer 2011; 104: 1160-1167.
84. Kondo S, Wakisaka N, Muramatsu M, et al. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J Virol 2011; 85: 11255-11264.
85. Port RJ, Pinheiro-Maia S, Hu C, et al. Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. J Pathol 2013; 231: 367-377.
86. Tsai CL, Li HP, Lu YJ, et al. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res 2006; 66: 11668-11676.
87. Dutton A, Woodman CB, Chukwuma MB, et al. Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007; 109: 2597-2603.
88. Scholle F, Bendt KM, Raab-Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 2000; 74: 10681-10689.
89. Fukuda M, Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt pathway. J Virol 2007; 81: 9299-9306.
90. Morrison JA, Raab-Traub N. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of ß-catenin signaling. J Virol 2005; 79: 2375-2382.
91. Fotheringham JA, Mazzucca S, Raab-Traub N. Epstein-Barr virus latent membrane protein-2A-induced ANp63a expression is associated with impaired epithelial cell differentiation. Oncogene 2010; 29: 4287-4296.
92. Fukuda M, Longnecker R, Latent membrane protein 2A inhibits transforming growth factor-ß1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 2004; 78: 1697-1705.
93. Moody CA, Scott RS, Amirghahari N, et al. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 2005; 79: 5499-5506.
94. Pegtel DM, Subramanian A, Sheen TS, et al. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol 2005; 79: 15430-15442.
95. Lu J, Lin WH, Chen SY, et al. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 2006; 281: 8806-8814.
96. Kong QL, Hu LJ, Cao JY, et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 2010; 6: e1000940.
97. Benders AA, Tang W, Middeldorp JM, et al. Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor-1a expression in nasopharyngeal carcinoma tissue. Head Neck Pathol 2009; 3: 276-282.
98. + cancer stem-like cells in EBV-associated nasopharyngeal carcinoma. PLoS One 2012; 7: e52426.
99. Lu QL, Elia G, Lucas S, et al. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993; 53: 29-35.
100. Rickinson AB. Co-infections, infammation and oncogenesis: future directions for EBV research. Semin Cancer Biol 2014; 26: 99-115.
101. Zhang G, Tsang CM, Deng W, et al. Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected prema-lignant and cancerous nasopharyngeal epithelial cells. PLoS One 2013; 8: e62284.
102. Liu P, Fang X, Feng Z, et al. Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology. J Virol 2011; 85: 11291-11299.
103. Kwok H, Tong AH, Lin CH, et al. Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy. PLoS One 2012; 7: e36939.
104. Tso KK, Yip KY, Mak CK, et al. Complete genomic sequence of Epstein-Barr virus in nasopharyngeal carcinoma cell line C666-1. Infect Agent Cancer 2013; 8: 29.
105. Kwok H, Wu CW, Palser AL, et al. Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. J Virol 2014; 88: 10662-10672.
106. Tsai MH, Raykova A, Klinke O, et al. Spontaneous lytic replication and epitheliotropism defne an Epstein-Barr virus strain found in carcinomas. Cell Rep 2013; 5: 458-470.